Neoplastic Condition Affecting Patents (Class 514/19.2)
-
Publication number: 20120039989Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
-
Publication number: 20120040914Abstract: A method of enhancing the effectiveness of a chemotherapeutic agent, such as Temozolomide (TMZ), or ionizing radiation against glioblastoma is described in the present invention. The method comprises targeting putative membrane androgen receptor (termed mAR) in glioma cells to enhance the cytotoxic effects of a chemotherapeutic agent or ionizing radiation while simultaneously affording protection to neighboring neurons.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTHInventors: MEHARVAN SINGH, Adrienne Badeaux, Niki Mirshams
-
Publication number: 20120034222Abstract: Medical devices having a catalyst capable of catalyzing the generation of nitric oxide in vivo and methods of treating a vascular condition using the devices are provided.Type: ApplicationFiled: October 19, 2011Publication date: February 9, 2012Applicant: Abbott Cardiovascular Systems, Inc.Inventors: Thierry Glauser, Stephen D. Pacetti, Paul Consigny
-
Patent number: 8110551Abstract: This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases.Type: GrantFiled: January 22, 2009Date of Patent: February 7, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Bruce Shenker, Kathleen Boesze-Battaglia
-
Patent number: 8110654Abstract: The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer.Type: GrantFiled: June 4, 2007Date of Patent: February 7, 2012Assignee: Peking University People;s HospitalInventors: Heng Cui, Wei Li, Xiaohong Chang, Jie Feng, Hongyan Cheng, Huifang Guo, Yexia Cheng
-
Publication number: 20120028908Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.Type: ApplicationFiled: October 1, 2011Publication date: February 2, 2012Applicant: Abbott LaboratoriesInventors: Shekhar VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Publication number: 20120028907Abstract: The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor prostate cancer patients for aggressive clinical treatment. The methods of the disclosure are applicable to ERGO tumors present in different human organs and tissues such as breast, lung, thyroid, ovary, and prostate.Type: ApplicationFiled: November 13, 2009Publication date: February 2, 2012Applicant: Intelligent Oncotherapeutics, Inc.Inventor: Stanley E. Shackney
-
Patent number: 8106002Abstract: The present invention provides anti-cancer agents comprising protein C inhibitor (PCI) or derivatives thereof as an active ingredient. The anti-cancer agents of the present invention have activities of suppressing cancer cell growth, and cancer metastasis, infiltration, and angiogenesis. Further, the present invention has shown that derivatives containing a heparin-binding domain of PCI inhibit the growth, metastasis and angiogenesis of cancer cells. Therefore, according to the present invention, PCI or derivatives thereof are useful for inhibiting the growth, metastasis and angiogenesis of cancer.Type: GrantFiled: April 18, 2006Date of Patent: January 31, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, Mie UniversityInventor: Koji Suzuki
-
Publication number: 20120021974Abstract: The invention relates to a method of treatment for states related to inhibition of angiogenesis and endothelial cell proliferation comprising administering an effective amount of vimentin or its derivatives or its fragments, to a subject in need thereof. Further, the invention relates to a pharmaceutical composition and a medicament comprising vimentin, as well as the use of vimentin in the manufacture of a medicament. Hereby, angiogenesis and endothelial cell proliferation can be controlled, and therapeutic treatment for related states is provided.Type: ApplicationFiled: July 4, 2008Publication date: January 26, 2012Applicant: IBCC HOLDING ASInventors: Taavi Pall, Wally Anderson, Lagle Kasak, Anne Pink, Priit Kogerman, Aire Allikas, Andres Valkna
-
Patent number: 8101165Abstract: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.Type: GrantFiled: April 13, 2007Date of Patent: January 24, 2012Assignee: NeovacsInventors: Jean Francois Zagury, Bernard Bizzini, Helene Le Buanec, Daniel Zagury
-
Publication number: 20120015887Abstract: A 4-copy branched peptide represented by a formula of (XA-XB-XC-XD-X1)4>(K-X2)2>K-X3. XA and XC separately represent an uncharged polar amino acid; XB and XD separately represent an alkaline amino acid; >K- represents lysine comprising two free activated amino groups for amino acid addition condensation reactions; X1 and X2 separately represents an amino acid sequence comprising between 0 and 5 random amino acids, and X1 and X2 are the same, different, or absent; and X3 is a sequence comprising between 1 and 4 random amino acids. The peptide is capable of inhibiting tumor growth and enhancing immunity.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Applicants: HEBEI YUANSEN PHARMACEUTICAL CO., LTD., YUANSENTAI BIOTECH (TIANJIN) INC.Inventors: Su HAN, Shoujun YUAN, Shunchang JIAO, Deqing TIAN
-
Patent number: 8097423Abstract: Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN/CA9 is not overexpressed. MN/CA9 gene expression products useful in the predictive/prognostic methods include MN/CA IX, MN proteins/polypeptides, MN nucleic acids and soluble MN/CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor.Type: GrantFiled: July 29, 2008Date of Patent: January 17, 2012Assignee: Institute of VirologyInventor: Adrian L. Harris
-
Publication number: 20120010149Abstract: The invention relates to a peptide combination characterized by peptides each having the same sequence length (SEQL), that can be produced from a mixture (A) comprising a number x of amino acids having a protected acid group or a number z of peptides having an acid group protected by means of a protecting group and an activated amino group, wherein the amino acids are present in the mixture (A) in particular adjustable molar ratios, and a mixture (B) comprising a number y of amino acids having an amino group protected by means of a protecting group, wherein the amino acid molar ratios of the mixture (B) are equal to the amino acid molar ratios of the mixture (A), and wherein the number x=y.Type: ApplicationFiled: December 30, 2009Publication date: January 12, 2012Applicant: GKL-Biotec AGInventor: Guenther Klett-Loch
-
Publication number: 20120009211Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.Type: ApplicationFiled: March 31, 2011Publication date: January 12, 2012Applicant: TOPOTARGET SWITZERLAND SAInventors: JÜRG TSCHOPP, PASCAL SCHNEIDER, NILS HOLLER
-
Patent number: 8093217Abstract: Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oligomers and derivatives of these oligomers, hyaluronan binding proteins, antibodies specific for hyaluronan receptors, hyaluronan mimetics, inhibitors of hyaluronan synthesis, and stimulators of hyaluronan degradation.Type: GrantFiled: April 29, 2004Date of Patent: January 10, 2012Assignee: Tufts UniversityInventors: Bryan P. Toole, Suniti Misra, Shibnath Ghatak
-
Publication number: 20120004175Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.Type: ApplicationFiled: March 28, 2008Publication date: January 5, 2012Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Zhiquan Zhang, Basil Rigas
-
Publication number: 20120003177Abstract: Curcumin, a polyphenol extracted from the rhizome turmeric, has been polymerized to produce a polymer material having a backbone of one or more repeating structural units, at least one of which comprises a curcumin monomer residue. These curcumin-containing polymers have a wide range of pharmacological activities, including, among others antitumor, antioxidant, antiinflammatory, antithrombotic and antibacterial activities. Certain species of these polymers have exhibited remarkable antitumor activity. Water-soluble curcumin derivatives and their use as prodrugs and prodrug carriers are also disclosed.Type: ApplicationFiled: September 17, 2009Publication date: January 5, 2012Inventors: Youqing Shen, Huadong Tang, Edward Van Kirk, William Murdoch, Maciej Radosz
-
Patent number: 8088412Abstract: A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.Type: GrantFiled: January 30, 2009Date of Patent: January 3, 2012Assignee: University of KansasInventors: Laird Forrest, Mark Cohen, Shuang Cai
-
Patent number: 8088737Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.Type: GrantFiled: April 2, 2004Date of Patent: January 3, 2012Assignee: Incyte CorporationInventors: Steven M. Friedman, Peggy A. Scherle, Xiangdong Liu, Timothy C. Burn, Reid Huber, Phillip C. C. Liu, Gregory F. Hollis, Krishna Vaddi, Jordan S. Fridman
-
Publication number: 20110319339Abstract: The present invention relates to a multimeric molecule having the general formula A or B: and its use in the diagnosis and/or therapy of tumors.Type: ApplicationFiled: November 4, 2009Publication date: December 29, 2011Inventors: Luisa Bracci, Alessandro Pini, Chiara Falciani, Stefano Menichetti
-
Publication number: 20110311445Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.Type: ApplicationFiled: May 9, 2011Publication date: December 22, 2011Applicant: MORPHOTEK, INC.Inventors: Vernon L. Alvarez, Matthew A. Gonda
-
Publication number: 20110300160Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.Type: ApplicationFiled: April 15, 2011Publication date: December 8, 2011Inventors: Joshua Rabbani, James J. Donegan
-
Patent number: 8071550Abstract: A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue.Type: GrantFiled: March 3, 2003Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventor: Rhett M. Schiffman
-
Publication number: 20110294720Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.Type: ApplicationFiled: December 1, 2009Publication date: December 1, 2011Applicant: University of Florida Research FoundationInventors: Hendrik Luesch, Liu Yanxia
-
Patent number: 8067000Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: May 22, 2009Date of Patent: November 29, 2011Assignee: New York UniversityInventors: Robert J. Schneider, Sumayah Jamal
-
Patent number: 8067375Abstract: Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.Type: GrantFiled: October 18, 2007Date of Patent: November 29, 2011Assignees: Biogen Idec MA Inc., University of North Carolina at Chapel HillInventors: Jeffrey L. Browning, Jenny P-Y Ting
-
Publication number: 20110288004Abstract: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.Type: ApplicationFiled: June 21, 2007Publication date: November 24, 2011Inventors: D. Grant McFadden, Alexandra R. Lucas, John W. Barrett
-
Publication number: 20110274623Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: April 29, 2011Publication date: November 10, 2011Inventor: Steven Jacobs
-
Patent number: 8053556Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.Type: GrantFiled: August 8, 2006Date of Patent: November 8, 2011Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
-
Patent number: 8048850Abstract: In one aspect, the invention provides covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins. In some embodiments, the covalent conjugates comprise artelinate and holotransferrin. In another aspect, the invention provides methods for administering the covalent conjugates of the invention to treat cancer and infections by pathogens that bind iron-carrying proteins.Type: GrantFiled: June 6, 2003Date of Patent: November 1, 2011Assignee: University of WashingtonInventors: Henry C. Lai, Tomikazu Sasaki, Narendra P. Singh
-
Patent number: 8048856Abstract: A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. The inventive hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision.Type: GrantFiled: July 11, 2011Date of Patent: November 1, 2011Assignee: Billion King, Ltd.Inventors: Bing Lou Wong, Sui Yi Kwok, Sze Hang Lau
-
Publication number: 20110262525Abstract: This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.Type: ApplicationFiled: December 11, 2007Publication date: October 27, 2011Applicant: SCHERING CORPORATIONInventors: Yan Wang, Chen Zong, Cynthia Seidel-Dugan, Yaolin Wang, Siu-Long Yao, Brian Der-Hua Lu, Mohamad H. Ladha
-
Publication number: 20110263513Abstract: Provided is the composition of a peptide and its mutagenic version, or other derivatives with the same 3-D structure with activity to bind the extracellular domain of PDGFR-?, or -?, but does not dimerize by itself, wherein said peptide comprises the sequence shown as SEQ ID NO: 1, 2 or 3. Also provided is the composition of the nucleotide sequence encoding said peptide and its derivatives, and the usage of said peptide and derivatives of the peptide in preparation of medicine for the prevention and treatment of fibrosis diseases, such as liver, kidney, and lung fibrosis, primary cancer, and cancer metastasis, especially stomach cancer, liver cancer, breast cancer, and lung cancer.Type: ApplicationFiled: September 21, 2009Publication date: October 27, 2011Inventors: Lan Huang, Hua Zhou, Shengtao Yuan
-
Publication number: 20110258713Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Applicant: VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao
-
Publication number: 20110257100Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.Type: ApplicationFiled: April 8, 2011Publication date: October 20, 2011Inventors: Stëphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frëdëric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Publication number: 20110257102Abstract: A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Inventors: Man-Sun Sy, Wei Xin, Chaoyang Li, Shuiliang Yi, Shaoman Yin
-
Patent number: 8039585Abstract: Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.Type: GrantFiled: February 12, 2004Date of Patent: October 18, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Karl G. Csaky, Hynda Kleinman, Lourdes Ponce
-
Publication number: 20110250180Abstract: The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).Type: ApplicationFiled: April 4, 2011Publication date: October 13, 2011Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCEInventor: Bruce L. RISER
-
Patent number: 8034781Abstract: The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.Type: GrantFiled: June 27, 2007Date of Patent: October 11, 2011Assignee: Wake Forest University Health SciencesInventors: E. Ann Tallant, Patricia E. Gallagher, Carlos M. Ferrario
-
Patent number: 8034779Abstract: A purified polypeptide includes an amino acid sequence consisting of about 10 to 80 amino acids, the amino acid sequence having a sequence identity at least 90% homologous to a portion of SEQ ID NO:1. The polypeptide inhibits binding of Bcl-2 to IP3 receptors of cells that express IP3R and Bcl-2 and induces apoptosis in a cell.Type: GrantFiled: August 13, 2008Date of Patent: October 11, 2011Assignee: Case Western Reserve UniversityInventors: Clark W. Distelhorst, Yiping Rong
-
Patent number: 8034780Abstract: Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.Type: GrantFiled: July 16, 2008Date of Patent: October 11, 2011Inventors: Kerry Leigh McPhail, Rebecca Ann Medina, William Henry Gerwick, Douglas Eugene Goeger, Todd Leo Capeon
-
Publication number: 20110245159Abstract: The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention also relates to polymorphs of these salts and solvates, pharmaceutical compositions containing these salts or solvates, and methods of using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics for a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, but not limited to, postoperative ileus, gastroparesis, including diabetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmotility, such as that occurring in conjunction with other disease states, in critical care situations or as a result of treatment with pharmaceutical agents.Type: ApplicationFiled: September 29, 2010Publication date: October 6, 2011Inventors: Hamid R. Hoveyda, Martin Vézina, Eric Fournier, René Gagnon, Patrick Bhérer
-
Publication number: 20110243937Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.Type: ApplicationFiled: May 26, 2011Publication date: October 6, 2011Applicant: PHIGENIX, INC.Inventor: Carlton D. DONALD
-
Publication number: 20110245176Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: November 12, 2010Publication date: October 6, 2011Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20110230418Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.Type: ApplicationFiled: August 19, 2005Publication date: September 22, 2011Applicant: The Research Foundation For Microbial Diseases Of Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto
-
Publication number: 20110229525Abstract: Cell penetrating suppressor of cytokine signaling (CP-SOCS) molecules engineered to be resistant to intracellular degradation are discussed. Methods of treating diseases associated with cytokine signaling include one or more CP-SOCS degradation resistant molecules.Type: ApplicationFiled: March 14, 2011Publication date: September 22, 2011Applicant: Vanderbilt UniversityInventors: Jack Jacek Hawiger, Antonio Digiandomenico
-
Publication number: 20110224133Abstract: This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP.Type: ApplicationFiled: July 24, 2009Publication date: September 15, 2011Inventors: Jae U. Jung, Jong-soo Lee
-
Publication number: 20110218138Abstract: The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.Type: ApplicationFiled: July 5, 2005Publication date: September 8, 2011Inventors: María Del Carmen Abrahantes Pérez, Jesús Reyes González, Gloria Véliz Rios, Eduardo Martínez Díaz, Caridad Anais Gasmuri González, José Garcia Suárez, Mónica Bequet Romero, Luis Javier González López, Lisa Rosa Castellanos Serra, Manuel Selman-Housein Sosa, Raúl Gómez Riera, Jorge Victor Gavilondo Cowley
-
Publication number: 20110218154Abstract: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo.Type: ApplicationFiled: February 17, 2011Publication date: September 8, 2011Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: STUART L. SCHREIBER, JACK TAUNTON, CHRISTIAN A. HASSIG, TIMOTHY F. JAMISON
-
Patent number: 8012465Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.Type: GrantFiled: July 28, 2009Date of Patent: September 6, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Laurence Elias, Gary Witherell